Skip to main content
. 2008 Dec;2(4):601–609. doi: 10.2147/btt.s2383

Table 4.

Grade III and IV toxicities observed in the phase III study of ranpirnase vs doxorubicin in MMe (according to the National Cancer Institute of Canada [NCIC] classification) (Vogelzang 2000)

Ranpirnase
G3 G4

Toxicity no. % no. %
Asthenia 9 10.8 1 1.2
Arthralgia/myalgia 4 4.8 0 0
Paresthesias 4 4.8 0 0
Dyspnea 4 4.8 0 0
Edema 2 2.4 0 0
Anaphylactoid reaction 0 0 1 1.2
Nausea and vomiting 0 0 1 1.2
Doxorubicin
G3 G4

Toxicity no. % no. %
Asthenia 2 4.5 0 0
Fever 2 4.5 1 2.3
Anorexia 1 2.3 0 0
Mucositis 1 2.3 0 0
Nausea and vomiting 1 2.3 1 2.3